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Vaccine adjuvant is conferred on the substance that helps to enhance antigen-speciﬁc immune response.
Here we investigated the disintegration characteristics and immunotherapy potency of an emulsiﬁed
delivery system comprising bioresorbable polymer poly(ethylene glycol)epolylactide (PEGePLA),
phosphate buffer saline (PBS), and metabolizable oil squalane. PEGePLA-stabilized oil-in-water emul-
sions show good stability at 4 C and at room temperature. At 37 C, squalane/PEGePLA/PBS emulsion
with oil/aqueous weight ratio of 7/3 (denominated PELA73) was stable for 6 weeks without phase
separation. As PEGePLA being degraded, 30% of free oil at the surface layer and 10% of water at the
bottom disassociated from the PELA73 emulsion were found after 3 months. A MALDI-TOF MS study
directly on the DIOS plate enables us to identify low molecular weight components released during
degradation. Our results conﬁrm the loss of PLA moiety of the emulsiﬁer PEGePLA directly affected the
stability of PEGePLA-stabilized emulsion, leading to emulsion disintegration and squalane/water phase
separation. As adjuvant for cancer immunotherapeutic use, an HPV16 E7 peptide antigen formulated
with PELA73 plus immunostimulatory CpG molecules could strongly enhance antigen-speciﬁc T-cell
responses as well as anti-tumor ability with respected to non-formulated or Alum-formulated peptide.
Accordingly, these advances may be a potential immunoregulatory strategy in manipulating the immune
responses induced by tumor-associated antigens.
 2013 The Authors. Published by Elsevier Ltd. Open access under CC BY-NC-SA license.1. Introduction
A vaccine contains an agent dubbed antigen that resembles a
disease-causing pathogen (e.g. bacterium, virus, or toxin) to elicit
adaptive immune responses. Vaccines have been commonly
applied to induce prophylactic immunity against infectious path-
ogens [1]. For therapeutic ends, there is a trend to generate infor-
mation derived from immunology to develop therapeutic vaccines
or immunotherapy technology against pathogen-associatedus Diseases and Vaccinology,
li, Taiwan. Tel.: þ886 37
. Huang).
r Ltd. Open access under CC BY-NC-SAcancers [2], and immune dysfunctions such as chronic inﬂamma-
tion and autoimmune disease [3]. Ideally, cancer immunotherapy
utilizes tumor-associated antigens to produce robust immunity and
anti-tumor efﬁcacy. However, recombinant protein or epitope
peptide-based immunotherapies have faced limited clinical success
caused by the relatively low immunogenicity, and hence require
the incorporation of adjuvants to elicit efﬁcient cytotoxic T
lymphocyte (CTL) activities against tumor cells [4,5].
Emulsions have been widely used in the immunotherapy and
vaccine development to enhance immune responses to co-
administered antigens [6]. In contrast to water-in-oil (W/O) emul-
sions, which foster local reactions at the injection site, O/W emul-
sions have the advantages of low oil content and high injectability
when performing vaccination [7]. Regarding the mechanisms of
adjuvant action, O/W emulsions possess high efﬁciency to the in-
duction of an early and strong cytokine- and chemokine-rich
environment at the site of injection, and beneﬁcial of modulation license.
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[8,9]. We have previously studied on the engineering of amphi-
philic bioresorbable polymers as a promising strategy for the de-
livery of vaccine antigens and/or immunostimulatory molecules
[10,11]. Ideally, bioresorbable polymeric emulsiﬁers, with a hydro-
phobic block that is degradable, show bulk degradation and further
resorb in vivo. This allows stabilization of emulsion particles during
storage, however, disintegration of the system post-injection.
Immunogenicity studies in mice by using ovalbumin and inﬂu-
enza as a model showed that bioresorbable polymers-stabilized
emulsions are able to induce potent antibody responses [10e13].
The degradation rate of a bioresorbable polymer implant has
been shown to correlate with cell vitality, cell growth and host
response [14], it is relatively important to evaluate the degradation
characteristics as well as the ﬁnal products of the designed poly-
mer for those applications in biomedical use. To the best of our
knowledge, the detail degradation characteristics of PEGePLA
were not fully investigated by matrix-assisted laser desorption/
ionization time-of-ﬂight (MALDI-TOF) technology. In addition,
whether degradation of polymeric emulsiﬁer can turn on the
emulsion disintegration during storage and post-injection is still
unknown. In this study, we plan to study the relation between
degradation of polymer and disintegration of emulsion. Moreover,
it is interesting to study on whether the bioresorbable polymer-
based vaccine adjuvant can enhance the cell-mediated responses
elicited by peptide antigen so as to be used as an immunotherapy
tool in suppressing tumor growth. Degradation of PEGePLA was
carried out in pure water at 25 C and 37 C selected to mimic the
usual storage conditions and the post-administration stage, and
followed by analytical techniques such as gel permeation chro-
matography (GPC) and MALDI-TOF mass spectrometry. In vivo
distribution was investigated in mouse model to elucidate the
targeting delivery of antigen-loaded systems bearing ﬂuorescence.
The immunogenicity studies in mice were investigated by
assessing the anti-tumor T-cell responses as well as the effec-
tiveness of these responses in inducing tumor regression. These
results were compared with those obtained from conventional
aluminum-based mineral salts (Alum) adjuvant and immunosti-
mulatory CpG oligodeoxynucleotides.
2. Materials and methods
2.1. Materials
DL-Lactide was purchased from Aldrich (Seelze, Germany) and recrystallized
from ethyl acetate. Polyethylene glycol 2000 monomethyl ether (MePEG2000) was
supplied by Fluka (Buchs, Switzerland) and used as received. Tin(II) 2-
ethylhexanoate (SnOct2), phosphate buffer saline (PBS), squalane, a-cyano-4-
hydroxycinnamic acid (CHCA), sodium triﬂuoroacetate (Na-TFA), dimethyl sulf-
oxide-d6 (DMSO-d6) were purchased from Sigma (St. Louis, Missouri, USA). All
solvents were of analytical grade. AB-type diblock copolymer PEGePLA was syn-
thesized by ring-opening polymerization of DL-lactide in the presence of MePEG2000
and SnOct2, as described previously [11].
2.2. Degradation of PEGePLA
5 mg of PEGePLA was dissolved in the eppendorf tube ﬁlled with 100 mL of
distilled, deionized water. The tubes were placed either at room temperature (25 C)
or in a circulating water bath at 37 C. At predetermined time points, three speci-
mens were collected and lyophilized before being subjected to analyses.
2.3. Measurements
GPC was performed by using a setting composed of an isocratic pump, a
refractive index (RI) detector, and two size exclusion columns connected in series,
one PLgel 5 mm guard column (7.5  50 mm), and one PLgel 5 mm mixed-D column
(7.5  300 mm). The mobile phase was tetrahydrofuran (THF) and the ﬂow rate was
1.0 mL/min. Datawere expressedwith respect to polystyrene standards (Varian, Inc.,
Amherst, MA, USA). 1H NMR spectra was recorded at room temperature with a
Varian VXR 300 MHz spectrometer (Varian, Palo Alto, CA, USA) using DMSO-d6 as a
solvent and tetramethylsilane as a shift reference. Mass spectra were acquired by
using the Micromass MALDI micro MX Time of Flight Mass Spectrometer(Waters, Milford, MA, USA) in the reﬂection mode. 1 mL aliquot of degradation
samples were premix with 1 mL of 0.2% TFA/acetonitrile andmixedwith CHCA as the
matrix and Na-TFA as the dopant. 1 mL aliquot of sample solutions were spotted on a
MALDI sample plate and air-dried to form a thin matrix/analyte ﬁlm. The degraded
samples without the matrix were deposited onto a plate containing porous silicone
spots (Waters MassPREP DIOS-target Plate, Milford, MA, USA) to monitor the
low molecular weight components.2.4. Polymer-stabilized emulsions
20 wt.% of PEGePLA/PBS was mixed with squalane oil in three oil/aqueous
weight ratios: 3/7, 5/5 and 7/3 (named PELA37, PELA55 and PELA73, respectively).
The mixtures were then emulsiﬁed using a Polytron PT 3100 homogenizer (Kine-
matica AG, Swiss) at 6000 rpm for 5 min. The resulting emulsions were served as a
stock for further characterizations such as the stability, the dispersion type, and the
particle size. The stability of emulsions was recorded by placing each sample at 4 C,
25 C and 37 C, and then noted the visual aspects. The dispersion types of the
emulsions were measured by using an ES-51 conductivity meter (HORIBA, Kyoto,
Japan). The emulsion was re-dispersed in PBS and then applied to monitor the
particle size by optical microscope (Olympus DP70, Olympus Inc., Tokyo, Japan) and
by laser light scattering technique (Brookhaven 90 plus particle size analyzer,
Brookhaven Instruments Limited, NY, USA).2.5. Peptides and cell line
Peptide used in this study is an H-2Db-restricted (RAHYNIVTF; RAH) CTL epitope
derived from the human papillomavirus (HPV) type 16 E7 protein, and was syn-
thesized in-house by solid phase method using an automated peptide synthesizer
(Prelude, Protein Technologies Inc., Tucson, AZ, USA), employing the Fmoc group
for a-amino group protection. The purity was >90% for the peptide.
Murine epithelial cell line transformed with the oncogenes Ras and HPV-16 E6
and E7, TC-1 (ATCC number: CRL-2785), was maintained in RPMI 1640 medium
supplemented with 2 mM L-glutamine, 1.5 g/L sodium bicarbonate, 4.5 g/L glucose,
10 mM HEPES, 1 mM sodium pyruvate, and 10% fetal bovine serum (JRH Biosciences,
Lenexa, KS, USA).2.6. Mice and ethic statement
Six-to-eight week-old female C57BL/6 mice were obtained from the National
Laboratory Animal Center. All mice were housed at the Laboratory Animal Facility of
the NHRI, Miaoli County, Taiwan. All animal studies were approved by the NHRI
Institutional Animal Care and Use Committee (NHRI-IACUC-098010-A).2.7. Immunization and T-cell immunity
Mice were immunized s.c. with 30 mg of RAH peptide in PBS or formulated with
300 mg/dose of aluminum phosphate suspension (ADJU-PHOS, Brenntag AG,
Frederikssund, Danish) or 10 mg/dose of CpG (50-TCC ATG ACG TTC CTG ACG TT-30
with all phosphorothioate backbones; synthesized by Invitrogen Taiwan Ltd.) or
PELA73 or PELA73/CpG combination adjuvant. The PELA73-containing formulations
were investigated by re-dispersing 100 mL of stock PELA73 emulsion into 900 mL of
vaccine bulk before injection.
Seven days after injection, spleen from the immunized mice was collected and
cell suspensions were harvested followed by resuspended in ACK lysis buffer
(consisting of 155 mM NH4Cl, 10 mM KHCO3, 0.1 mM EDTA) for 1 min. Single cell
suspensions (5  105 cells) were re-stimulated in triplicate in the presence or
absence of 10 mg/mL target RAH peptide. Interferon (IFN)-g- and interleukin (IL)-4-
secreting cells were analyzed by enzyme-linked immunosorbent spot (ELISPOT)
assay (eBioscience, San Diego, USA) and the concentration of released cytokine in
culture medium was quantiﬁed by enzyme-linked immunosorbent assay (ELISA)
(R&D systems, Minneapolis, Minnesota, USA).
For ELISPOT analysis, cells and medium were decanted from the capture anti-
body coated plates after culturing in a 5% CO2 incubator at 37 C for 3 days. After
washing, biotinylated detection antibody was added to the plates and incubated at
room temperature for 2 h and then the antibody solution was decanted. After
another 45 min of incubation at room temperature with AvidineHRP conjugate,
freshly prepared AEC substrate solution (Sigma, Saint Louis, MO, USA) was added
and allowed to develop color at room temperature for 40 min. By monitoring
development of spots, the substrate reaction was stopped by washing wells 3 times
with distilled water. The spots were then counted by using an automated ELISPOT
plate reader (Cellular Technology Ltd., Shaker Heights, OH, USA). The numbers of
cytokine-secreting splenocytes were calculated as the average of spots in the trip-
licate stimulant wells. Cell-depleted supernatants were analyzed by ELISA devel-
opment kit using paired antibodies following the manufacturer’s instructions. The
assay was developed by adding aqueous tetramethylbenzidine substrate solution
(TMB, NeA-Blue, Clinical Science Products, Inc. Mansﬁeld, MA, USA), and the re-
action was stopped in 2 N H2SO4. Plates were read at 450 nm on an ELISA plate
reader (Molecular Devices, Sunnyvale, CA, USA).
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Mice were ﬁrst inoculated s.c. with 2  105 or 5  105/mouse TC-1 tumor cells
into the ﬂank. Upon the appearance of palpable tumors, the C57BL/6 mice were
injected s.c. at the base of the tail with 10 mg of RAH peptide on day 7. Tumor sizes
weremeasured by using a caliper (Digimatic Caliper, Mitutoyo, Japan) in two vertical
dimensions two times per week. Tumor volumes were calculated according to for-
mula: (length  width2)/2. Mouse was euthanized when tumor volume exceeded
2500 mm3 or severe faintness. Median survival was calculated by GehaneBreslowe
Wilcoxon method.
2.9. Statistical analysis
The graphs and statistical analyses were performed using GraphPad Prism
version 5.02 (GraphPad Software, Inc.). Comparison of survival curve between
groups was calculated by use of log-rank (MauteeCox) test. Comparison of T-cell
immune responses between groups was determined by ManneWhitney test. The
differences were considered signiﬁcant as P < 0.05.
2.10. IVIS spectrum imaging analysis
Mice were injected subcutaneously (s.c.) at the dorsal regionwith 10 mg of RAH-
Alexa Fluor647 (absorption 650 nm; ﬂuorescence emission 668 nm, synthesized by
GeneDireX, Taoyuan, Taiwan) or 10 mg of CpG-cy5 (absorption 650 nm; ﬂuores-
cence emission 668 nm, synthesized by GeneDireX, Taoyuan, Taiwan) either with
PBS (200 mL, control experiment) or supplemented with PELA73 emulsion diluted in
PBS (20 mL/180 mL). Mice were anesthetized with isoﬂurane at a maintenance con-
centration of 2.5%, and oxygen pressurized at 4 kg/cm2 in conjunction with XGI-8
Anesthesia System. In-life ﬂuorescence analysis was performed at 7, 30, 48, 72,
and 144 h after treatment using a Xenogen IVIS Spectrum 200 Imaging System
(Caliper Life Sciences, USA). The ﬂuorescent measurement was quantiﬁed using IVIS
Living Image 4.0 software package.
3. Results
3.1. Formulation and physicochemical characterization of polymer-
based emulsions
The emulsiﬁer used here has initial molecular characteristics of
75 wt.% of hydrophilic block PEG and 25wt.% of lipophilic block PLA
with GPC molecular weight of 3850 Da and polydispersity of 1.1.
Squalane was selected as the core oil because it is very stable and
not susceptible to oxidation. It is also referred metabolizable in
human and currently has been used as a skin moisturizer in cos-
metics and as an adjuvant in vaccines [15]. Table 1 summarizes the
physicochemical characteristics of the emulsiﬁed formulations
comprising PBS, PEGePLA copolymer, and squalane.
Dynamic light scattering showed the polymeric aqueous solu-
tion (20 wt.%) possessing a unimodal distribution with an average
diameter of 13 nm (Table 1), probably due to the micelle formation
of the block copolymer by packing of the hydrophobic PLA block
[10]. By incorporating the squalane into the polymeric aqueous
solution, phase separation occurs due to immiscible of squalane
and water. Followed homogenization under gentle conditions, a
white and isotropic emulsion was rendered. We thus termed the
PEGePLAeemulsiﬁed adjuvant as PELA37 when the oil/aqueous
weight ratio being 3/7. Upon storage at room temperature, 35% of
water disassociated from the bottom of the PELA37 emulsionTable 1
Physicochemical characteristics of the emulsiﬁed formulations comprising bio-
resorbable polymer PEGePLA, phosphate buffer saline, and metabolizable oil
squalane.
Acronym Component O/W (w/w) Electrolytic
conductivity
(ms/m)
Particle size (nm)
Oil phase Water phase
PBS e e PBS e 125 nd
Micelles e PEGePLA PBS e 135 10e15
PELA37 Squalane PEGePLA PBS 3/7 61 400e700
PELA55 Squalane PEGePLA PBS 5/5 24 400e710
PELA73 Squalane PEGePLA PBS 7/3 12 350e580
Squalane Squalane e e e 0 nd
nd: Non-detectable.within 24 h, but beyond this, no further water disassociation from
the emulsion occurred. Increasing the squalane content could
signiﬁcantly enhance the stability of the squalane/water interface.
When oil/aqueous weight ratio being 7/3 (denominated PELA73), a
stable emulsion was formed without phase separation for at least 6
months’ storage. Concerning the dispersion type of the emulsions,
it is generally recognized that an emulsion of zero conductivity will
tend to be water dispersed in the oil, otherwise oil dispersed in the
water [16]. As listed in Table 1, squalane and PBS have conductivity
of 0 ms/m and 125ms/m, respectively. The electrolytic conductivity
of the emulsions with different oil/aqueous ratios was measured as
61 ms/m (PELA37), 24 ms/m (PELA55), and 12 ms/m (PELA73),
indicating more oil content leads to lower conductivity. Moreover,
the three emulsions were well dispersed in aqueous solution. These
results revealed the dispersion type of squalane/PEGePLA/PBS
emulsions belongs to the O/W emulsion type. The particle size of
the different oil/aqueous ratio emulsions was further investigated
by optical microscope and laser light scattering technology. As
shown in Fig.1 and Table 1, squalane/PEGePLA/PBS emulsions were
general unimodal with the size distribution between 400 and
700 nm no matter what the oil/aqueous ratio changes.
3.2. Hydrolytic degradation of PEGePLA and disintegration of PEGe
PLA-based squalane emulsion
Fig. 2A and B presents the GPC and of MALDI-TOF proﬁles of
PEGePLA during degradation in distilled deionized water at 37 C.
As shown in Fig. 2A, themolecular weight (MW) decreasewas rapid
at the early stages. The number-average molecular weight (Mn)
decreased from initial 3850 to 3300 at week 2 and to 2850 at week
6. Afterwards, the decrease rate slowed down.Mn¼ 2800 and 2750
were detected after 3 months and 6 months respectively. To pre-
cisely realize the degradation characteristics of the PEGePLA block
copolymer, we monitor the detail molecular weight changes by
MALDI-TOF mass spectrometry. As shown in Fig. 2B, the MePEG2000
spectra were well resolved, and the peaks were separated by 44
mass units, which corresponded to the MW of the EG monomer
(oxyethylene units ¼ 44.03 g/mol). After polymerizing with DL-
lactide, other peaks separated by 72 mass units appeared (lactyl
units¼ 72.06 g/mol), in agreement with the presence of PLA blocks.
After 2 weeks’ degradation at 37 C, the peaks corresponded to
lactyl units strongly decreased, indicating the loss of PLA compo-
nent. Beyond 3 months, no signal characteristics of PLA were
detected on the MALDI-TOF mass spectra, in agreement with GPC
data. In the absence of matrix-related background, desorption-
ionization mass spectrometry on porous silicon is able of moni-
toring low molecular weight components released during degra-
dation [17]. On the MALDI-TOF spectra of PEGePLA, no peak
corresponding to LA oligomers was detected in the range between
100 m/z and 900 m/z at the very beginning (Fig. 2B, left panel),
indicating the elimination of low molecular weight species during
puriﬁcation. There was a burst at week 1, i.e. in the period where
important changes occurred. As degradation proceeded, the peaks
of LA oligomers kept high intensity at week 2 andweek 6. However,
there were no typical LA bands detected on the spectrum beyond 3
months, in agreement with GPC data. MALDI-TOF data showed that
large amounts of PLA oligomers broke away from PEGePLA be-
tween week 1 and week 6. Beyond, ester bond cleavage of PLA
oligomers takes place continuously to further degradation, sug-
gesting PLA preserved its degradability.
The degradation rate was strongly reduced as the temperature
decreased from 37 C to 25 C. As shown in Fig. 3A, Mn decreased
progressively from initial 3850 to 3550 at week 2 and to 3350 at
week 6. Mn ¼ 3200 and 2900 were detected after 3 months and 6
months respectively. Similar features are noted for MALDI-TOF
Fig. 1. (A) Microscopic aspect and (B) laser light scattering analysis of the emulsiﬁed vaccine formulations. Homogeneous ﬁne particles with mean size ranged from 400 to 700 nm
were observed in the PELA37-emulsiﬁed formulations (blue, left), while 350e580 nm were found for the PELA73-emulsiﬁed ones (green, right). In the case of PELA55 (yellow,
middle), a bimodal distribution with two different sizes was observed, the relatively small particles of 450 nm and larger ones of 600 nm. Data are representative for at least ﬁve
independent experiments. (For interpretation of the references to color in this ﬁgure legend, the reader is referred to the web version of this article.)
Fig. 2. Hydrolytic degradation of PEGePLA and disintegration of PEGePLA-based squalane emulsion at 37 C. In vitro hydrolytic degradation of PEGePLA was performed in distilled
deionized water at 37 C. Degradation products were recovered by lyophilization and monitored by GPC and MALDI-TOF. (A) Degradation samples were frozen dried then re-
dissolved in 1 mL of THF and applied to GPC at 1.0 mL/min ﬂow rate. (B) 1 mL of each sample was applied to form complex with matrix. Dried matrix/analyte complex was
used to MALDI-TOF analysis under reﬂection mode. Lowmolecular weight components were measured on a plate containing porous silicone spots without matrix. (C) Visual aspects
of the emulsion upon storage at 37 C for six months.
W.-L. Chen et al. / Biomaterials 35 (2014) 1686e1695 1689
Fig. 3. Hydrolytic degradation of PEGePLA and disintegration of PEGePLA-based squalane emulsion at 25 C. In vitro hydrolytic degradation of PEGePLA was performed in distilled
deionized water at 25 C. Degradation products were recovered by lyophilization and monitored by GPC and MALDI-TOF. (A) Degradation samples were frozen dried then re-
dissolved in 1 mL of THF and applied to GPC at 1.0 mL/min ﬂow rate. (B) 1 mL of each sample was applied to form complex with matrix. Dried matrix/analyte complex was
used to MALDI-TOF analysis under reﬂection mode. Lowmolecular weight components were measured on a plate containing porous silicone spots without matrix. (C) Visual aspects
of the emulsion upon storage at 25 C for six months.
W.-L. Chen et al. / Biomaterials 35 (2014) 1686e16951690analysis (Fig. 3B). After two weeks, PEGePLA still showed similar
MALDI distribution as the beginning, beyond, the decrease of PLA
peaks was detected from 6 weeks to 6 months. Very small amount
of peaks corresponding to PEGePLA were still detectable under 6
months’ degradation. Concerning the low molecular weight spe-
cies, the peaks of LA oligomers kept high intensity during the
whole degradation period (Fig. 3B, left panel), indicating a differ-
entiation between 25 C and 37 C.
Since the interface between squalane and PBS was stabilized by
the bioresorbable polymer PEGePLA, we attempt to investigate
the relationship between the degradation of PEGePLA and the
stability of squalane/PEGePLA/PBS emulsions. The emulsiﬁed
PELA73 was separately stored in 4 C, 25 C and 37 C and
recorded the visual aspects. An isotropic emulsion was last at least
1 year at 4 C and sustained for 6 months of storage at 25 C
(Fig. 3C). On the other hand, the bottom water layer and the sur-
face free oil were dissociated from the emulsion at 3 month and 6
month while stored at 37 C (Fig. 2C). It is noteworthy that the
time points of the emulsion disintegration were correlated with
the PEGePLA degradation proﬁles. To verify the disintegration of
the emulsion was caused by the degradation of the emulsiﬁer
PEGePLA, we further analyzed the residues existed in the disso-
ciated water layer by MALDI-TOF mass spectra. Data showed that
peaks corresponding to LA motif in PEGePLA were fully dis-
appeared in the residues, i.e. no additional peaks other than
MePEG2000 (Fig. 4). These results indicate the loss of PLA moiety of
PEGePLA directly affected the stability of PEGePLA-stabilized
emulsion, leading to disintegration of PELA73 and phase separa-
tion of squalane/water.3.3. Antigen-speciﬁc T-cell immune responses and tumor regression
efﬁcacy
HPVs have been known the most common sexually transmitted
infections and are responsible for most of cervical cancer cases [18].
We applied cancer immunotherapy of RAHYNIVTF peptide/TC-1
cells as tumor-associated antigen/tumor cells model to evaluate
the adjuvanticity of PELA73 [19].
Firstly, RAHwas s.c.-injected into C57BL/6mice. Seven days after
the immunization, single-cell suspensions were prepared from the
mouse spleen and re-stimulated in vitro in the presence of peptide
antigen. The cytokine-secreting responses were detected by ELI-
SPOT and ELISA assays. As shown in Fig. 5A, vaccination of 30 mg of
RAH peptide alone or formulated with PELA73 showed no effect on
the enhancement of IFN-g-secreting cells compared with the naïve
group. The group treatedwith conventional adjuvants such as Alum
and CpG ODN (oligodeoxynucleotide containing unmethylated
cytosine-guanosine motifs [20]) induced higher spot numbers
(75  6 and 126  9 spots per 106 splenocytes, respectively) than
peptide alone, indicating that the two adjuvants could trigger the
RAH-speciﬁc T-cell activation. Interestingly, the highest IFN-g-
secreting cells are obtained in the group of combination of PELA73
and CpG (387  7 spots per 106 splenocytes), which was 5 times
more than Alum and 3 times higher than CpG alone group. Fig. 5B
showed the concentration of released IFN-g in culture medium by
splenocytes after re-stimulated by peptides for 3 days. The same
tendency as ELISPOT assay was found, i.e. co-administration of RAH
with the combination of PELA73 and CpG induced the most IFN-g
release compared with those adjuvanted with CpG, PELA73, or
Fig. 5. IFN-g secretion of spleen cells following immunization with RAH peptide antigen. C57BL/6 mice were vaccinated once subcutaneously with 30 mg/dose of RAH peptide, alone
or formulated with various adjuvants. Seven days after the immunization, splenocyte suspensions were incubated in the presence or absence of 10 mg/mL of RAH peptide. (A) IFN-g-
producing cells were assessed by ELISPOT assays of cell suspensions for 72 h of culture. (B) Supernatants collected from triplicate cultures at day 3 were assessed by IFN-g ELISA. The
data are expressed as the mean plus the standard errors of duplicate assays.
Fig. 4. Schematic presentation and MALDI-TOF mass spectra of the components in the water layer of PELA73 emulsion. (A) Starting PEGePLA, (B) Disintegration at 37 C for 6
months. The residues existed in the dissociated water layer were recovered by lyophilization and measured by MALDI-TOF. No signals characteristic of LA were detected on the
spectra, indicating the loss of PLA component.
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W.-L. Chen et al. / Biomaterials 35 (2014) 1686e16951692Alum adjuvant. Nevertheless, the IL-4 cytokine was found to be at
the undetectable level.
The tumor challenge was carried out in mouse model to eval-
uate the therapeutic potential of our adjuvant-formulated cancer
vaccine. C57BL/6micewere ﬁrst inoculatedwith 2105/mouse TC-
1 tumor cells then immunized RAH peptide at day 7. The tumor
volume and survival rate were followed and recorded in Fig. 6.
Without any treatment (PBS control group), tumors grew pro-
gressively and themice started lethal within 30 days (Fig. 6A and B).
No protection was observed for the mice received RAH peptide
alone. Peptide adjuvanted with Alum slightly slowed tumor growth
and prolonged survival, but all mice were still lethal before day 60.
Vaccination with RAH peptide plus CpG provided better protective
effect than adjuvanted with Alum, but still not good enough to
eliminate inoculated TC-1 cells. The mice received RAH peptide
formulated with PELA73 neither decreased the mortality nor
reduced the tumor volume, nevertheless, it is noteworthy the
combination of PELA73 and CpG was able to efﬁciently eliminate
most TC-1 cells which was better than CpG alone. The average tu-
mor volume of PELA73/CpG group was less than 100 mm3 until day
52 with respect to day 38 of the CpG group. We further challenge
mice by inoculating 5  105/mouse TC-1 cells (i.e. 2.5 folds higher
than preliminary test) to distinguish the adjuvanticity between CpG
alone and PELA73/CpG. Results showed that the mice received
single injection of RAH (10 mg) adjuvanted with PELA73/CpG
strongly slow down the tumor volume increase when compared
with those adjuvantedwith CpG alone (Fig. 6C). It is noteworthy the
PELA73 really broadens the immunostimulatory efﬁcacy of CpG and
prolong the median survival of TC-1-bearing mice from 56 days to
92 days (Fig. 6D).Fig. 6. Antitumor efﬁcacy of different adjuvant-formulated RAH peptide on C57BL/6 mice b
cells (2  105 cells/mouse). Upon the appearance of palpable tumors, eight mice per grou
adjuvant on day 7. Tumor sizes were assessed twice per week using calipers to determine
inoculated s.c. in the ﬂank with 5  105 TC-1 tumor cells per mouse. On day 7, eight mice
adjuvant or PELA73/CpG combination. Data are expressed as the mean value  standard d3.4. Biodistribution imaging of emulsiﬁed particles in mice
In vivo distribution was investigated in mouse model to eluci-
date the targeting delivery of antigen-loaded systems bearing
ﬂuorescence, using Alexa Fluor647-conjugated RAH peptide
(RAH-Alexa 647) as model antigen. Mice were immunized s.c. with
10 mg RAH-Alexa 647, either with antigen in PBS or formulated with
PELA73 or PELA73/CpG. As shown in Fig. 7A, the ﬂuorescence signal
was initially induced in the site of injection. At 7 h, the signal as
shown in the representative image dropped dramatically in the
RAH-Alexa 647-treated and PELA73/RAH-Alexa 647-injected mice.
No signals characteristic of Alexa Fluor were detected on the IVIS
spectra beyond 30 h, indicating the absence of RAH-Alexa 647. The
ﬂuorescence signals of RAH-Alexa 647 are not inﬂuenced by the
presence of PELA73 emulsion via subcutaneous route. Nevertheless,
we found that the ﬂuorescence signals of RAH-Alexa 647 via i.m.
injection are strongly inﬂuenced by the presence of PELA73
emulsion, thus providing prolonged release proﬁle of hydrophilic
RAH peptide. (see Supplementary information Fig. S1).
We also attempt to focus on the distribution of ﬂuorescence-
labeled CpG (CpG-cy5) within PELA73 emulsion by the IVIS sys-
tem. Mice were immunized s.c. with 10 mg CpG-cy5 either in PBS or
formulated with PELA73. The ﬂuorescence signals of CpG-cy5 in
PBS were dramatically attenuated after 30 h then returned to
baseline within approximately 144 h following injection. On the
other hand, the ﬂuorescence signals were slightly decreased for the
CpG-cy5/PELA73 injected mice (Fig. 7B). Our results demonstrated
PELA73 provided a depot for bioactive agent CpG at injection site
via s.c. administration so as to prolong sufﬁcient immunomodula-
tory responses against cancer.earing TC-1 tumor cells. (A, B) Mice were inoculated s.c. in the ﬂank with TC-1 tumor
p were injected s.c. at the tail base with 10 mg/dose of RAH peptide with or without
the volume of each tumor. The tumor volumes are shown (mm3). (C, D) Mice were
per group were injected s.c. at the tail base with 10 mg/dose of RAH peptide with CpG
eviation. *P < 0.05.
Fig. 7. In vivo distribution of (A) RAH-Alexa 647 and (B) CpG-cy5 in mice. C57BL/6 mice were injected s.c. with 10 mg of RAH-Alexa 647 or CpG-cy5 and imaged at 0, 7, 30, 48, 72, and
144 h after injection by IVIS system.
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The synthesis and degradation proﬁles of bioresorbable polymer
were monitored mainly by GPC chromatography and/or combined
with NMR method [21e23]. However, a precise characterization of
amphiphilic copolymer is not very easy because it is difﬁcult to
distinguish on the NMR spectra whether the recovery samples are
of copolymer form or a mixture. For the ﬁrst time, we investigate
the hydrolytic degradation characteristics of amphiphilic PEGePLA
block copolymer by GPC and MALDI-TOF mass spectrometry. The
results (Figs. 2 and 3) indicate the time points of the emulsion
disintegration were highly correlated with the PEGePLA degrada-
tion proﬁles. In addition, no signals characteristic of LA were
detected on the MALDI-TOF spectra of the residues existed in the
dissociated water layer. The loss of PLA moiety of the emulsiﬁer
PEGePLA directly affected the stability of PEGePLA-stabilized
emulsion, leading to disintegration of PELA73 and phase separation
of squalane/water. Concerning the effect of temperature on PLA
degradation, hydrolytic cleavage rate of ester bond in the polymer
backbone could be acceleratedwith an increase in temperaturewas
also reported in the cases of PLA homo/copolymer bulk materials
[24,25].
Broadly speaking, vaccine adjuvants can be separated into two
classes based on their principal mechanisms of action: immunos-
timulatory adjuvants and particulate delivery systems. In contrast
to the former which are thought to trigger a sufﬁcient activation of
the innate immune systems, the latter are generally particulate andmainly function as a depot to ensure the immunoavailability of
antigen [26]. The conventional Alum adjuvant had been used many
decades and been shown to enhance antibody responses, however,
often been considered as a poor adjuvant to induce CD8 T-cell
activation [27,28]. Based on our immunogenicity studies, we also
demonstrated antigen formulated with Alum can slightly trigger T-
cell immune response (Fig. 5). Unfortunately, the immunity elicited
by Alum-formulated RAH peptide was neither inhibit tumor
growth nor tumor regression (Fig. 6A). To bypass these limitations,
combination adjuvants which consist of particulate delivery system
and immunostimulatory compound can be considered as an
interesting alternative to deliver antigen/immunostimulator effec-
tively to the receptors of the immune cells and/or to generate the
number of the receptors [13,29]. For example, prophylactic
Cervarix HPV vaccine, which is approved by US FDA, contains
recombinant HPV type 16 L1 protein, type 18 L1 protein, and
combination adjuvant (dubbed AS04) comprising of aluminum
hydroxide and monophosphoryl lipid A. Some cross-reactive pro-
tection against virus strains type 31 and type 45were also shown in
clinical trials [29]. On the other hand, it is well-documented in
literature that immunostimulatory CpG oligodeoxynucleotides are
agonists of intracellular receptor TLR9 that can induce the activa-
tion of antigen-presenting cells and Th1-dominated immune
response [20]. However, CpG has been shown to be degraded
rapidly in vivo by nucleases, leading to the reduction of the desired
immune response [30]; therefore, it requires some protecting
vesicles to prolong its efﬁcacy. In the present study, we increase the
W.-L. Chen et al. / Biomaterials 35 (2014) 1686e16951694immunogenicity of HPV16 E7(49e57) peptide antigen by using
emulsiﬁed microencapsulation technology. PELA73 facilitates the
IFN-g-secreting responses elicited by CpG, leading to generate the
valuable tumor inhibition and tumor regression characters (Figs. 5
and 6). In fact, IFN-g is a predominant T helper type 1 (Th1) cyto-
kine applicable to CTL activity against tumor cells [31], while IL-4 is
a common T helper type 2 (Th2) cytokine relevant to humoral
immunity. Effective vaccination was correlated with the induction
of the Th1 cytokines (including IFN-g), especially in the immuno-
logically hyporesponsive populations such as the elderly and
tumor-bearing host [32,33]. Therefore, increasing IFN-g induction
via vaccination is thought to be an important strategy for over-
coming the tumor progression.
For vaccine or protein delivery, polymers have mostly been
elaborated in the form of injectable micro- or nano-spheres or
implant systems [34]. The major obstacle of such systems is the
complicated fabrication processes using organic solvents, which
may cause denaturation when antigens (or biologically active
agents) are to be formulated. The use of amphiphilic polymers as
surfactants differs from those for vaccine delivery and represents a
new area with signiﬁcant potential. One example is TiterMax,
wherein a squalene-based W/O emulsion is stabilized by micro-
particulate silica and non-ionic block copolymer Pluronic [35].
Although TiterMax elicits potent immune responses more than
emulsiﬁed formulations based on low-molecular weight surfac-
tants, however, Pluronic are non-degradable and enhance plasma
cholesterol and triglycerol after intraperitoneal injection in rat [36].
To meet the above needs, we introduced amphiphilic bioresorbable
polymers to comprise the efﬁcacy and safety of the polymers. We
have previously studied the effects of bioresorbable polymer-based
emulsion on the activation and antigen-presenting functions of
bone marrow-derived dendritic cells (BMDCs) [10,26]. Our ﬁndings
indicate that these formulations were biologically inert in BMDCs.
In the present study, IVIS data demonstrated PELA73 provided a
depot for bioactive agent CpG at injection site via s.c. administra-
tion (Fig. 7) and RAH peptide via i.m. injection (Fig. S1). With these
features in mind, emulsiﬁed delivery system could serve as eitherScheme 1. Representation of degradation of PEGePLA and disintegraticarrier or vehicle to deliver biologically active agents (e.g. antigens
and immunostimulatory adjuvants) to immune cells in a targeted
and prolonged manner, thus effectively probing and manipulating
the vaccine immunogenicity. Concerning the size of the particles,
several studies have veriﬁed that the small solutes or nanoparticles
(<50 nm) are internalized by antigen-presenting cells (APCs)
through macropinocytosis, whereas submicron particles
(>500 nm) can be internalized by APCs through phagocytosis
without speciﬁc recognition has been reported in the literature
[37,38]. It should be noted that the dimensions of squalane/PEGe
PLA/PBS emulsion particles are proper sizes for internalization by
APCs to facilitate the induction of cell-mediated immunity (Fig. 1).
Based on these results, we found the PEGePLA-stabilized emulsion
have several advantages including proper size for cell uptake, stable
for long-term storage, and disintegratable post-injection. Scheme 1
summarizes the degradation of PEGePLA and disintegration of
PEGePLA-based squalane emulsion following immunization. The
submicron emulsion is stable during storage and disintegratable
post-injection. PEGePLA-based emulsion serves as an antigen de-
livery system to favor the cell uptake, hence it triggers efﬁcient
anti-tumor immunity while formulated with HPV16 E7(49e57)
peptide and CpG immunostimulator. These advances open up a
new approach to the development of immunotherapy technologies
against tumor challenge.
5. Conclusions
Disintegration characteristics and cancer immunotherapy po-
tency of the PEGePLA-emulsiﬁed antigen delivery systems were
investigated. The results showed that squalane/PEGePLA/PBS
emulsions are stable during storage and disintegratable post-
injection. As adjuvant for immunotherapeutic use, we also
demonstrated that PEGePLA-based emulsion is a promising strat-
egy to deliver the designed signals alongwith peptide antigens. Our
ﬁndings indicated that bioresorbable polymer-emulsiﬁed formu-
lations present great interest as injectable carriers as well as
effective inducer to elicit speciﬁc T-cell response and therapeuticon of PEGePLA-based squalane emulsion following immunization.
W.-L. Chen et al. / Biomaterials 35 (2014) 1686e1695 1695ability in mice. These advances offer the potential in developing
therapeutic cancer vaccine in the future. Further investigations are
under way to combine the immunotherapy with cancer chemo-
therapeutic agents such as paclitaxel to prolong the survival of
tumor-bearing mice.
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